M&A · Healthcare · Pharmaceutical Preparations
Pharmacosmos A/S to acquire G1 Therapeutics, Inc.
Announced Aug 7, 2024 · Closed Sep 18, 2024
Deal value$405MEV $428M
Premium68.0%To unaffected price
EV / Adj. EBITDA—5.1x EV / Revenue
ConsiderationAll cash$7.15 per share
Transaction
- Acquirer
- Pharmacosmos A/S
- Target
- G1 Therapeutics, Inc. (GTHX)
- Buyer type
- Strategic
- Offer price per share
- $7.15
- Enterprise value
- $428M
- Status
- Closed Sep 18, 2024
Deal protections
- Break fee (target pays)
- $12.2M · 3.0%
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- No financing condition
Advisors
- To the acquirer
- Not disclosed
- To the target
- Centerview
- Centerview fee
- $14.9M
Sector context · Healthcare
- Comparable deals
- 104 in the prior 24 months
- Premium
- 68.0% vs. 63.5% sector median
- EV / Adj. EBITDA
- Sector median 17.2x
- Break fee
- 3.0% vs. 3.5% sector median
Timeline
- AnnouncedAug 7, 2024
- Tender offerAug 20, 2024
- ClosedSep 18, 2024
Valuation · fairness opinions
Trading comparables$2.60$5.25
Precedent transactions$4.85$6.80
Discounted cash flow$4.90$5.60
Analyst price targets$2.50$6.00
Offer $7.15
Implied value per G1 Therapeutics, Inc. share by analysis, from Centerview · DCF discount rate 13%–16%.